In summary, our results unravel an unrecognized off-target effect of class A ODN on suppressing the cGAS level and signaling in FRC, which provides critical information for designing class A ODN therapies for inflammatory diseases and cancer in the future. This evidence concerns the gene CGAS and cancer.